GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging
Blood Sugar Climbs For people with type 2 diabetes who take Ozempic to manage their blood sugar, halting treatment may cause blood sugar to rebound to around pre-medication levels, says Beverly Tchang, MD, an endocrinologist and an assistant professor at NewYork-Presbyterian and Weill Cornell Medicine in New York City
The primary outcome was percentage weight loss after 68-week treatment on an intention-to-treat analysis
Xenical prevents the dietary fat from being absorbed into the bloodstream, thus leading to weight loss
In my recent podcast, Feeling Off After GLP-1s, I discussed this disorientation
This is why semaglutide is generally considered a long-term medication rather than a short-term solution